About Trius Therapeutics (NASDAQ:TSRX)
Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions
What is Trius Therapeutics' stock symbol?
Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."
Who are some of Trius Therapeutics' key competitors?
Some companies that are related to Trius Therapeutics include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam (ABC), Auxilium Pharmaceuticals (AUXL), Horizon Therapeutics (HPTX), Myovant Sciences (MYOV), Anika Therapeutics (ANIK), Vitae Pharmaceuticals (VTAE), Sinovac Biotech (SVA), ChemoCentryx (CCXI), 3SBio (SSRX), Kadmon (KDMN), Strongbridge Biopharma (SBBP), Syros Pharmaceuticals (SYRS), Kamada (KMDA), Mereo BioPharma Group (MPH) and Syndax Pharmaceuticals (SNDX).
How do I buy Trius Therapeutics stock?
Shares of Trius Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Trius Therapeutics?
Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.
MarketBeat Community Rating for Trius Therapeutics (TSRX)MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trius Therapeutics (NASDAQ:TSRX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Trius Therapeutics (NASDAQ:TSRX) Earnings History and Estimates Chart
Trius Therapeutics (NASDAQ TSRX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/6/2013||Q212||($0.33)||($0.41)||$3.71 million||$1.30 million||View||N/A|
Trius Therapeutics (NASDAQ:TSRX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Trius Therapeutics (NASDAQ:TSRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Trius Therapeutics (NASDAQ TSRX) Insider Trading and Institutional Ownership History
Trius Therapeutics (NASDAQ TSRX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|7/22/2013||John Finn||Insider||Sell||1,000||$12.10||$12,100.00|| |
|7/15/2013||John Finn||Insider||Sell||3,500||$10.55||$36,925.00|| |
|7/12/2013||John Finn||Insider||Sell||6,500||$9.81||$63,765.00|| |
|7/11/2013||Michael Morneau||CAO||Sell||20,000||$9.75||$195,000.00|| |
|7/1/2013||Philippe Prokocimer||Insider||Sell||2,000||$8.14||$16,280.00|| |
|6/12/2013||John Finn||Insider||Sell||3,000||$9.08||$27,240.00|| |
|6/11/2013||John Finn||Insider||Sell||1,000||$8.94||$8,940.00|| |
|6/4/2013||Ken Bartizal||Insider||Sell||2,000||$7.90||$15,800.00|| |
|6/3/2013||Philippe Prokocimer||Insider||Sell||2,000||$7.75||$15,500.00|| |
|5/24/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.93||$95,160.00|| |
|5/14/2013||Ken Bartizal||Insider||Sell||12,000||$7.85||$94,200.00|| |
|5/14/2013||Michael Morneau||CAO||Sell||20,000||$7.75||$155,000.00|| |
|5/13/2013||Philippe Prokocimer||Insider||Sell||12,000||$7.65||$91,800.00|| |
|5/10/2013||John Finn||Insider||Sell||3,000||$7.48||$22,440.00|| |
Trius Therapeutics (NASDAQ TSRX) News Headlines
Trius Therapeutics (NASDAQ:TSRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Trius Therapeutics (NASDAQ:TSRX) Income Statement, Balance Sheet and Cash Flow Statement
Trius Therapeutics (NASDAQ TSRX) Stock Chart for Wednesday, January, 17, 2018